论文部分内容阅读
目的:比较头孢哌酮舒巴坦单用和联合阿米卡星治疗泛耐药铜绿假单胞菌(PDRPA)所致医院获得性肺炎(HAP)的疗效。方法:将2012年6月至2013年12月份收治的84例PDRPA-HAP患者分为单用组(单用头孢哌酮舒巴坦)和联合组(头孢哌酮舒巴坦联合阿米卡星)。参照卫计委制定的《抗生素临床研究指导原则》相关标准评价抗感染疗效。结果:两组细菌清除率比较,差异有统计学意义(χ2=5.765,P=0.016);临床疗效比较,差异无统计学意义(χ2=2.791,P=0.095);药品不良反应比较,差异无统计学意义(P>0.05)。结论:头孢哌酮舒巴坦联合阿米卡星治疗PDRPA-HAP的细菌清除率优于单用头孢哌酮舒巴坦,值得进一步扩大研究观察。
Objective: To compare the efficacy of cefoperazone and sulbactam alone and in combination with amikacin in the treatment of hospital acquired pneumonia (HAP) caused by pan-resistant Pseudomonas aeruginosa (PDRPA). Methods: Eighty-four patients with PDRPA-HAP admitted from June 2012 to December 2013 were divided into single-use group (cefoperazone sulbactam alone) and combination group (cefoperazone-sulbactam combined with amikacin ). Reference to the formulation of the “Health Guidelines for Antibiotics,” the relevant standards of anti-infective evaluation. Results: There was significant difference in bacterial clearance between the two groups (χ2 = 5.765, P = 0.016). There was no significant difference in clinical curative effect between the two groups (χ2 = 2.791, P = 0.095) Statistical significance (P> 0.05). Conclusion: Cefoperazone sulbactam combined with amikacin treatment of PDRPA-HAP bacterial clearance rate is superior to cefoperazone sulbactam alone, it is worth further study.